An interventional study of transcranial magnetic stimulation in Schizophrenia, Functional Magnetic Resonance Imaging and Transcranial Magnetic Stimulation, sponsored by WANG KAI. Completed at 1 site in China. Open to participants aged 18 Years to 52 Years. Per ClinicalTrials.gov, last updated 2021-04-15.
Sponsored by WANG KAI · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 252 studies in Schizophrenia with a site in China — 64 open to participants now, 68 under way, 4 of them phase 3. Schizophrenia · China.
Among the 252 studies in Schizophrenia with a site in China, this one is the 149th largest by enrollment of the 216 interventional ones that give a count, is one of 15 that started in 2017, is one of 110 with no phase, and was the 111th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →64 of the 252 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:
Central South University · Sites in China
Ages 18–35
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–60
Central South University · Sites in China
Ages 18–50
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–60
Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 52 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
252 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 16 · Phase 3 38 · Phase 4 33
First in 2002; this study’s year is marked. 15 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 216 interventional studies, 300 across the 36 observational. Of the 120 that completed or were terminated, 21 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 252 have an industry lead sponsor. The 10 most frequent:
WANG KAI is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
WANG KAI has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
19 of the studies in Schizophrenia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112067Shanghai Mental Health CenterEfficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders | 2026-11 |
| NCT07521683NeuShen TherapeuticsA Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia | 2026-11 |
| NCT06802939Shanghai Mental Health CenterRTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography | 2026-12-10 |
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT07356765Tianjin Anding HospitalBerberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms | 2027-01 |
Add all 19 to your calendar (.ics) → With an account.
Among the 252 studies in Schizophrenia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the treatment effect of intermittent theta-burst transcranial magnetic stimulation on symptomatic relief of schizophrenia patients, and the underlying neural mechanism by functional MRI and the resting electroencephalogram
All patients underwent a medical evaluation that included physical examination and routine laboratory studies before and after intermittent theta-burst transcranial magnetic stimulation (iTBS) treatment. Patients were randomly allocated to iTBS group and the sham group by coin toss. There are about 30 patients in each group.The decision to enroll a patient was always made prior to randomization. Patients were studied using a double-blind design. Study participants, clinical raters, and all personnel responsible for the clinical care of the patient remained masked to allocated condition and allocation parameters. Only iTBS administrators had access to the randomization list; they had minimal contact with the patients, and no role in assessing the Positive and Negative Syndrome Scale (PANSS). Each patient would be treated for continuous 14 days by iTBS.Before the iTBS treatment, PANSS and Clinical Global Impression-severity of illness (CGI-SI) at baseline were obtained by a trained investigator to assess baseline severity of their symptoms. Scale for the Assessment of Negative Symptoms (SANS) and Scale for Assessment of Positive Symptoms (SAPS) were respectively supplemented to evaluate the severity of symptoms in different dimensions,.The patients had receiving a battery measure of neuropsychological tests (standardized tests to investigate their cognitive problems, anxiety and depressive symptoms in daily life), magnetic resonance imaging scan in multimodalities, electroencephalography (EEG), event-related potentials during stop signal test and Iowa-gambling test record. Other behavioral tests including intertemporal decision,spatial n-back test record.
After the last treatment, the Positive and Negative Syndrome Scale were obtained, as well as the Global Index of Safety to assess adverse events of the treatment. Patients were instructed to focus their answers on the past 14 days. The patients had also receiving a battery measure of neuropsychological tests, magnetic resonance imaging scan in multimodalities, and EEG record.Clinical Global Impression-global improvement (CGI-GI), Clinical Global Impression-efficacy index (CGI-EI) were evaluated at the end of treatment.
40-60 days after the last treatment, participants were interviewed to obtain the Positive and Negative Syndrome Scale,SAPS,SANS and HAMA,HAMD. They were instructed to focus their answers on the past week. Additionally, they were also asked to assess the battery of neuropsychological tests, and have magnetic resonance imaging scan in multimodalities, and EEG record. Afterwards, they were unblinded by the study coordinator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Real Stimulation: active transcranial magnetic stimulation(Intermittent Theta Burst Stimulation).Participants will receive active TMS once daily for two weeks
Device: transcranial magnetic stimulation
Sham Stimulation:no stimulation.Participants will receive sham TMS once daily for two weeks
Device: transcranial magnetic stimulation
The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks. Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks
Positive And Negative Syndrome Scale(PANSS)
The improvment in PANSS scores will constitute the major research outcome measure used to assess response to rTMS,reflecting the symptom improvment in patients
Time frame: Baseline and 2 weeks post-treatment,and follow-up
Scale for the Assessment of Positive Symptoms (SAPS)
The improvment in SAPS scores will constitute the major research outcome, and specifically reflect the degree of improvement in patients' positive symptoms
Time frame: Baseline and 2 weeks post-treatment and follow-up
Scale for the Assessment of Negative Symptoms (SANS)
The improvment in SANS scores will constitute the major research outcome, and specifically reflect the degree of improvement in patients' negative symptoms
Time frame: Baseline and 2 weeks post-treatment and follow-up
Functional connectivity change of transcranial magnetic stimulation(iTBS and sham)
Functional MRI measures: the functional connectivity between stimulated target and the whole brain areas
Time frame: Baseline and 2 weeks post-treatment
EEG change of transcranial magnetic stimulation(iTBS and sham)
EEG measures: brain areas wave change of stimulation(iTBS and sham)
Time frame: Baseline and 2 weeks post-treatment
Intertemporal decision test
Intertemporal decision test is associated with the function of left dorsolateral prefrontal cortex
Time frame: Baseline and 2 weeks post-treatment
Spatial n-back test
Spatial n-back test will reflect the prefrontal function
Time frame: Baseline and 2 weeks post-treatment
Multidimensional Empathy Test
Multidimensional empathy Test is associated with the function of left dorsolateral prefrontal cortex
Time frame: Baseline and 2 weeks post-treatment
Ran from May 2017 to primary completion in Jul 2020, 37 months.
Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 37 months is above that.
Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
WANG KAI